CureDuchenne is recognized as a global leader in research, patient care, and innovation for improving and extending the lives of those with Duchenne muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 individuals living today. CureDuchenne is dedicated to finding and funding a cure for Duchenne by breaking the traditional charitable mould through an innovative venture philanthropy model that funds groundbreaking research, early diagnosis, and community education.
TREAT-NMD are very grateful to the ongoing support that CureDuchenne offers to academic groups working on treatments or platform technologies for Duchenne muscular dystrophy.
Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne serves on the core committee of the TREAT-NMD Advisory Committee for Therapeutics.